These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 19597153)

  • 1. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.
    Seike M; Goto A; Okano T; Bowman ED; Schetter AJ; Horikawa I; Mathe EA; Jen J; Yang P; Sugimura H; Gemma A; Kudoh S; Croce CM; Harris CC
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12085-90. PubMed ID: 19597153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mathematical model for microRNA in lung cancer.
    Kang HW; Crawford M; Fabbri M; Nuovo G; Garofalo M; Nana-Sinkam SP; Friedman A
    PLoS One; 2013; 8(1):e53663. PubMed ID: 23365639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.
    Chen G; Umelo IA; Lv S; Teugels E; Fostier K; Kronenberger P; Dewaele A; Sadones J; Geers C; De Grève J
    PLoS One; 2013; 8(3):e60317. PubMed ID: 23555954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-30b inhibits non-small cell lung cancer cell growth by targeting the epidermal growth factor receptor.
    Qi Z; Zhang B; Zhang J; Hu Q; Xu F; Chen B; Zhu C
    Neoplasma; 2018; 65(2):192-200. PubMed ID: 29534579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
    Xia J; Luo M; Dai L; Wang L; Wang L; Zhu J
    J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
    Cho WC; Chow AS; Au JS
    Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
    Zeng Z; Chen HJ; Yan HH; Yang JJ; Zhang XC; Wu YL
    Int J Biol Markers; 2013 Sep; 28(3):249-58. PubMed ID: 23873621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells].
    Guo YH; Gao FH; Shi J; Yuan HH; Jiang B
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):187-92. PubMed ID: 23879998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.